Results 81 to 90 of about 22,236,668 (323)
Background/Objectives: Chimeric antigen receptor T-cell (CAR-T) therapy has been approved for the management of relapsed and refractory hematologic malignancies, transforming the oncologic landscape and producing durable remissions in patient populations
Stella O. Oyewole +3 more
doaj +1 more source
Dopaminergic pathway is the most disrupted pathway in the pathogenesis of Parkinson's disease. Several studies reported associations of dopaminergic genes with the occurrence of adverse events of dopaminergic treatment.
Sara Redenšek +7 more
doaj +1 more source
Referral Patterns and Diagnostic Timeliness in Pediatric Cancer: A Hospital‐Based Study in Indonesia
ABSTRACT Background Timely diagnosis and treatment are critical for improving survival among children with cancer. In low‐ and middle‐income countries (LMICs), delays are common and may be influenced by fragmented referral pathways and diagnostic limitations.
Nur Melani Sari +5 more
wiley +1 more source
PurposeTo capture UK societal health utility values for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and the disutility associated with treatment-related adverse events (AEs) to inform future cost–utility analyses.MethodsA literature ...
F. Hall +9 more
semanticscholar +1 more source
Summary of the treatment-related adverse events.
Summary of the treatment-related adverse events.
Oluf Dimitri Røe (109870) +13 more
core +1 more source
Drug-related adverse events necessitating treatment discontinuation in pediatric inflammatory bowel disease patients. [PDF]
BACKGROUND AND AIMS Inflammatory bowel disease (IBD) requires long-term drug therapy in most patients, posing a risk for adverse drug events with the need for discontinuation.
Spalinger, J. +29 more
core +2 more sources
ABSTRACT Relapsed and/or refractory (R/R) pediatric acute leukemia carries a dismal prognosis, largely driven by chemoresistance to conventional salvage therapy. The BH3‐mimetic venetoclax, combined with chemotherapy or hypomethylating agents, has demonstrated efficacy in small clinical trials.
Katherine S. Colman +9 more
wiley +1 more source
Descriptive summary of treatment-related adverse events.
Descriptive summary of treatment-related adverse events.
Zhifeng Li (1776799) +6 more
core +1 more source
Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
Background: Immune checkpoint inhibitors (ICIs) emerged as the preferred therapy in advanced lung cancer, understanding the treatment- and immune-related adverse events of these drugs is of great significance for clinical practice. Materials and methods:
Jun Shao +5 more
semanticscholar +1 more source
ABSTRACT Febrile neutropenia (FN) is a frequent and serious complication in children receiving cancer therapy. Standardizing FN management across Asia is challenging due to variable healthcare infrastructure, diagnostic capacity, and infection patterns; however, it could improve resource use and patient outcomes.
Joliza Patricia Cañeba +29 more
wiley +1 more source

